Pulmocide today announces the successful dosing PC945 in a phase 1 study.

PC945 is a novel antifungal agent which is delivered by inhaled administration for
the treatment of Aspergillus Fumigatus infections of the respiratory tract. PC945
exhibits excellent safety and lung retention characteristics. This is associated with
minimal systemic exposure which avoid the safety and drug interaction liability
concerns observed with systemic antifungal treatments